June 19th- Post-ASCO and EHA 2026: Multiple Myeloma at the Immunotherapy Crossroads

CME Congresses .

June 19th- Post-ASCO and EHA 2026: Multiple Myeloma at the Immunotherapy Crossroads

June 14th- LIVE from #EHA26- SUCCESSOR-2: Has Mezigdomide Just Redefined Relapse Therapy in Multiple Myeloma?

CME Congresses .

June 14th- LIVE from #EHA26- SUCCESSOR-2: Has Mezigdomide Just Redefined Relapse Therapy in Multiple Myeloma?

June 13th- LIVE from #EHA26- MonumenTAL-3: is Talquetamab Redefining Early Relapse Myeloma?

CME Congresses .

June 13th- LIVE from #EHA26- MonumenTAL-3: is Talquetamab Redefining Early Relapse Myeloma?

June 13th- LIVE from #EHA26- frontMIND: The First Real Challenge to R-CHOP in High-Risk DLBCL?

CME Congresses .

June 13th- LIVE from #EHA26- frontMIND: The First Real Challenge to R-CHOP in High-Risk DLBCL?

June 10th- Dr. Rahul Banerjee- Elra real world

CME Congresses .

June 10th- Dr. Rahul Banerjee- Elra real world

June 8th- Beyond the Webinar: Coagulopathy in Acute Leukemia: When Minutes Matter More Than Molecules

CME Congresses .

June 8th- Beyond the Webinar: Coagulopathy in Acute Leukemia: When Minutes Matter More Than Molecules

June 5th- Beyond the Webinar: Apheresis: The Forgotten Backbone of Cellular Therapy

CME Congresses .

June 5th- Beyond the Webinar: Apheresis: The Forgotten Backbone of Cellular Therapy

June 2nd- LIVE from #ASCO26- Philadelphia-Positive ALL: The End of Chemotherapy and the Beginning of a New Era?

CME Congresses .

June 2nd- LIVE from #ASCO26- Philadelphia-Positive ALL: The End of Chemotherapy and the Beginning of a New Era?

June 1st- LIVE from #ASCO26- frontMIND: The First Real Challenge to R-CHOP in High-Risk DLBCL?

CME Congresses .

June 1st- LIVE from #ASCO26- frontMIND: The First Real Challenge to R-CHOP in High-Risk DLBCL?

May 31st- ASCO 2026: Teclistamab Changes the Rules at First Relapse — The Practice-Changing MajesTEC-9 Trial

CME Congresses .

May 31st- LIVE from #ASCO26- Teclistamab Changes the Rules at First Relapse — The Practice-Changing MajesTEC-9 Trial